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gel on Escherichia coli O157:H7 and on the activity
of Shiga toxins
Tomás Subils*, Cecilia Casabonne and Claudia BalaguéAbstract
Background: Shiga toxin-producing Escherichia coli (STEC) is the causative agent of hemolytic uremic syndrome
(HUS). Colloidal bismuth hydroxide gel (CBHG) is an anti-diarrheal and antisecretory compound, which does not
inhibit gastrointestinal motility and reaches an in vivo gut concentration of 10.8 mg/ml of bismuth. Its action on
bacteria has not been studied. We analyzed its inhibitory effects on STEC, as well as the deactivation of the Shiga
toxin (Stx) and its ability to block the spread of genes encoding Stx. We determined a minimum inhibitory concentration
and bactericidal concentration for the STEC O157:H7 strain (EDL933), with CBHG and Chobet® bismuth cream with pectin
(CBCHP). We analyzed its effect on Stx by means of cytotoxicity assay and ELISA, as well as its effect on the free 933 W
Stx phage.
Results: Effect on the EDL933 strain: CBHG: MIC 10 mg/ml of bismuth. CBCHP: MIC 6 mg/ml and MBC 15 mg/ml of
bismuth. Effect on EDL933 virulence factors: significant decrease in active Stx and 933 W Stx phage titer. ELISA did not
find significant differences with treatment.
Conclusions: The results obtained may be useful in the development of new therapeutic strategies based on the use of
CBHG to prevent or improve the prognosis of HUS, as it can be used to control STEC infections.
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Hemolytic uremic syndrome (HUS) is a clinical and ana-
tomopathological entity characterized by the acute mani-
festation of kidney damage, microangiopathic hemolytic
anemia and thrombocytopenia. It may also affect other
parenchymas such as the intestine, pancreas, heart and
central nervous system [1].
Shiga toxin-producing Escherichia coli (STEC) is reported
to be the most significant causative agent of HUS, whereas
E. coli 0157:H7 is the prevalent serotype. STEC has been
identified as one of the emerging pathogens with the great-
est impact on foodborne infections. Although these patho-
genic strains produce several virulence factors, the main
virulence factor is the Shiga toxin (Stx), an A-B-type toxin
that inhibits protein synthesis in target cells. The Stx pro-
duced by STEC in the intestine are believed to enter the* Correspondence: tomassubils@hotmail.com
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unless otherwise stated.systemic circulation and cause damage to distant organs,
especially the kidneys. Some studies suggest that the risk of
serious complications in STEC infection, such as HUS, is
related to the presence and quantity of Stx produced during
the infection [2]. There are two main types of Stx in these
strains, encoded on the stx1 and stx2 genes, which have
a 56% homology, and each of them has more than one
closely related variant [3]. Other genes may contribute
to the virulence of the aforementioned strains, particu-
larly the eae gene, which encodes the intimin protein that
facilitates the binding of the bacterium to epithelium of
the intestine; and an enterohemolysin (gene ehxA) [4,5].
Both E. coli O157:H7 and the Stx-encoding phages or
bacteriophages play a prominent role in the spread of
virulence genes between different species of bacteria, in
hosts and in the environment [6].
In Argentina, HUS is endemic and is the main cause
of pediatric acute kidney failure [7] and the second cause
of chronic kidney failure, making it responsible for 20%
of transplants in children and adolescents [8]. Sometd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Argentina are similar to the reference STEC strain
EDL933 [9]. To date, a specific treatment for HUS has
not yet been developed, and some data have shown that
the use of antibiotics in infected children increases the risk
of developing the disease [10]. The exposure of E. coli
O157:H7 strains to antibiotics can lead to the increased
spread of phages and Stx production [11,12].
In Argentina, Chobet® bismuth cream with pectin
(CBCHP) has been prescribed as an anti-diarrheal drug for
oral use for over 60 years. CBCHP does not inhibit intes-
tinal motility and contains 30 mg/ml of colloidal bismuth
hydroxide gel (CBHG) and pectin as active ingredients.
Furthermore, bismuth compounds have been used ex-
tensively in gastroenterology. Previous studies in patients
found bismuth absorption in the large intestine of below
1% and a theoretical concentration of 10.8 mg/ml [13].
Tests have also been done on the interaction of bismuth
salts with fruit juices, ascorbic acid and thiols for the pur-
pose of producing active, soluble bismuth products. The
interaction of salts with thiol-containing molecules is due
to the high affinity of the bismuth ion for sulfhydryl
groups [14]. The antibacterial activity of the bismuth
ion is lower as an inorganic salt and requires high con-
centrations. Some studies suggest that this activity can
be increased by the use of lipophilic thiol agents [15].
In this regard, the use of CBHG has been demonstrated
to generate antibacterial activity without the need for high
concentrations.
Many epidemiological studies have confirmed the effi-
cacy of treatments with bismuth compounds for the pre-
vention of traveler’s diarrhea, particularly for the various
virotypes of E. coli, Salmonella spp. and Shigella spp.
[16,17]; for the treatment of acute diarrhea from rotavirus
and enterotoxigenic E. coli in children [18-20]; and as a
supplement in the treatment of gastric and duodenal ulcers
from Helicobacter pylori [21], among other applications.
Despite this vast and extensive background in the use
of bismuth compounds for the prevention and treatment
of diarrhea, there is still controversy regarding their com-
plete mechanism of action. Some studies have indicated that
bismuth compounds inhibit the intestinal secretion caused
by Vibrio cholerae and enterotoxigenic E. coli toxins
[22] and decrease the cell invasion of enteroinvasive E. coli
[23]. Also, bismuth enhances the opsonophagocytosis of
Klebsiella pneumoniae, thereby reducing the expression
of the capsule [24], and reversibly represses the expres-
sion of fimbriae in enteropathogenic and uropathogenic
E. coli strains [25]. A study by Brogan et al. [26] showed
dithiol bismuth to be an inhibitor of the Rho protein of
E. coli, an essential protein that controls the expression
of several genes in Gram-negative bacteria. Thus, the
inhibitory and antibacterial activity of bismuth compounds
is believed to be the result of multiple mechanisms.The aim of this study was to seek potential therapeutic
strategies for the prevention and treatment of HUS,
studying the effect of CBHG in clinical and subclinical
concentrations on the viability and on the principal
pathogenicity factors of a reference STEC strain.
Methods
Bacterial strain and bismuth compounds
We studied Chobet® bismuth cream with pectin (CBCHP)
(Soubeiran Chobet, S.R.L., City of Buenos Aires, Argentina)
because this is the only medicinal specialty with colloidal
bismuth hydroxide gel (CBHG) as active ingredient with a
concentration equivalent to 30 mg/ml of metallic bismuth.
We used E. coli O157:H7 reference strain ATCC 43895
(EDL933) characterized by PCR for the presence of O157,
stx1 and stx2.
Determination of sensitivity to bismuth compounds
We determined the minimum inhibitory concentration
(MIC) and minimum bactericidal concentration (MBC)
of CBHG and CBCHP in Mueller-Hinton broth of the
strains studied [27,28]. We started from 0.5 McFarland
bacterial suspension. For the MIC test, MH-agar plates
with different concentrations of bismuth were seeded by
drop. We worked with dilutions of 1/50, 1/25, 1/15, 1/
10, 1/5 and 1/3, which correspond to bismuth concen-
trations of 0.6, 1.2, 2, 3, 6 and 10 mg/ml, respectively.
Meanwhile, in the case of MBC, MH-broth tubes with
serial dilutions of bismuth were inoculated, incubated
overnight at 37°C and grown in MH-agar plates in ab-
sence of bismuth. The dilutions used were 1/32, 1/16,
1/8, 1/4 and 1/2, which are equivalent to bismuth con-
centrations of 0.94, 1.88, 3.75, 7.5 and 15 mg/ml,
respectively.
Determination of bacterial attachment to the bismuth
suspension
The bacterial culture (1010 bacteria/ml) was incubated with
and without bismuth compounds at a subinhibitory con-
centration (2 mg/ml) in LB medium at 37°C for 18 hours
with shaking. Samples were then collected at specific time
intervals (6, 24 and 168 hours) to determine the total num-
ber of viable microorganisms, while other samples were
centrifuged at 1000 rpm for 5 minutes. Supernatant bac-
teria were considered not attached and they were counted
on agar plates [28]. The number of attached bacteria was
obtained by subtracting the number of not attached bac-
teria from the total viable bacteria.
Effect of Stx expression according to cytotoxicity assay
The E. coli O157:H7 EDL933 strain was cultivated in LB
medium at 37°C for 18 hours with shaking. The bacterial
culture was diluted in 5 ml of LB broth together with the
bismuth compounds to be analyzed: CBHG in dilutions of
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of 6 and 10 mg/ml, respectively; and CBCHP in dilutions
of 1/10 and 1/3, which are equivalent to bismuth concen-
trations of 3 and 10 mg/ml, respectively. They were then
incubated for 18 hours at 37°C with stirring at 140 rpm.
We performed a positive control without bismuth com-
pounds, negative controls without bacterial culture for
each compound and concentration used, as well as a
double negative control without bismuth compounds
or bacterial culture. The cultures were centrifuged at
8,000 rpm for 10 minutes at 4°C, whereas the supernatants
were separated, filtered through a 0.43 μm membrane and
the bacterial presence controlled in MH-agar [29].
We used the technique of 96-well microplates seeded
by co-culture of Vero cells with the samples [30]. The
Vero cells grew in a minimum essential medium (MEM,
Sigma 0643) (with 200 mg/l of streptomycin and 100 mg/l
of penicillin), to which 10% fetal bovine serum (FBS) was
added at 37°C with 5% of CO2. The cells were detached
using trypsin and were transferred to an MEM without
SFB. We inoculated 100 μl of a 2.5 × 106 cells/ml suspen-
sion in each of the microplate’s wells.
Next, we seeded the samples of the supernatants from
the bacterial cultures and made dilutions (1, 1/2, 1/4, 1/
8 and 1/16) with MEM with 15% FBS. The microplates
were incubated at 37°C with 5% of CO2, and readings
were taken at 48 h with an inverted microscope. The
percent cytotoxicity is an estimate of the cell monolayer
destruction. We then determined the titer of 50% cyto-
toxic activity (DC50). The cells were stained and fixed
with 0.75% violet crystal solution in 40% methanol [31].Determination of Stx concentration by means of enzyme
immunoassay
We used the RIDASCREEN® Verotoxin (R5701, R-
Biopharm Latinoamérica S.A., City of Buenos Aires,
Argentina) test to detect Stx1 and Stx2. Following the
manufacturer’s specifications, we assayed the superna-
tants of the bacterial cultures treated 18 h with CBHG
(6 mg/ml) to determine extracellular Stx. Measurements
were taken photometrically with a wavelength of 450 nm.
The average was calculated and compared with untreated
bacterial cultures.Table 1 MIC, MBC and percentage of bacterial attachment to
Bacterial
strains
Concentration of bismuth (mg/ml)
CBHG1 CBCHP2
MIC3 MBC4 MIC3 MBC
STEC EDL933 10 Higher than the dose 6 15
*p < 0.05, 1CBHG: colloidal bismuth hydroxide gel; 2CBCHP: Chobet® bismuth cream
bactericidal concentration.Effect on free phage 933 W
We analyzed the effect of CBHG and CBCHP on the
Stx-encoding lambda 933 W phage. We titered and in-
cubated the phage suspension with the aforementioned
compounds at four different dilutions: 1/24, 1/12, 1/6
and 1/3, which correspond to bismuth concentrations of
1.25, 2.5, 5 and 10 mg/ml, respectively, for 24 hours at
37°C with continuous shaking. Later, we confirmed the
presence of the phages by means of the double-agar layer
technique, using E. coli DH5α as the indicator strain and
we determined the number of lysis plates formed (plaque
forming units - PFU/ml) [32].
Statistical analysis
All tests were performed independently five times, and
the data were statistically evaluated by variance analysis,
followed by the Tukey-Kramer multiple comparison test.
Results
Study of the effect on STEC
When we performed the inhibition assays with CBHG,
we observed an MIC corresponding to 10 mg/ml of
bismuth for the reference STEC strain. However, MBC
was not detected for the doses studied. In the case of
CBCHP, we observed an MIC corresponding to 6 mg/ml
of bismuth for the STEC and a MBC corresponding to
15 mg/ml of bismuth. CBHG exhibited a greater degree of
bacterial attachment (p < 0.05) than CBCHP. At the same
time, CBHG attachment remained almost constant over
time (about 90 to 98%). With CBCHP, we observed a sta-
tistically significant increase (p < 0.05) in the percentage
(from 22.9 to 41.1%) of cells attached from 6 to 24 h, and
then the attachment rate leveled out (Table 1). No signifi-
cant difference was observed in the number of viable
microorganisms attached without bismuth compounds,
under the conditions applied.
Study of the effect on pathogenicity factors of E. coli
O157:H7
We observed a significant reduction (p < 0.05) in the ac-
tive Stx titer in the samples treated with a 1/5 dilution of
CBHG, which corresponds to a bismuth concentration of
6 mg/ml; and with a 1/10 dilution of CBCHP, which is
equivalent to a bismuth concentration of 3 mg/ml. TheseCBHG and CBCHP
Colony forming units attached (%)
CBHG1 CBCHP2
4 Incubation time Incubation time
6 h 24 h 168 h 6 h 24 h 168 h
89.6* 94.1* 97.7* 22.9 41.1* 41.4*
with pectin. 3MIC: minimum inhibitory concentration; 4MBC: minimum
Table 2 Effect of CBHG and CBCHP on Stx in Vero cells,
expressed as cytotoxicity percentages
Dilutions
of toxins





6 mg/ml 3 mg/ml 3 mg/ml 1.5 mg/ml
1/2 80 20 80 50a* 100
1/4 80 − 80 20 50a
1/8 50a − 60 − 50
1/16 50 − 50a − −
1/32 − − − − −
a50% cytotoxicity dose (CD50), *p < 0.05,
1CBHG: colloidal bismuth hydroxide
gel; 2CBCHP: Chobet® bismuth cream with pectin.
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could inhibit Stx activity. However, no significant differ-
ences were observed at lower concentrations (Table 2).
The following changes were observed by means of optical
microscopy (Figure 1): brightness and progressive detach-
ment of cells from monolayer, formation of cell surface in
folds with multiple blebs, and finally release of several
membrane-bound apoptotic bodies. The apoptotic cells
were characterized by condensed chromatin, intensive
nuclear fragmentation, cytoplasmic organelle disruption,
formation of apoptotic bodies and cell shrinkage [33].
However, when quantifying free Stx on supernatants,
the enzyme immunoassay test yielded no significant dif-
ferences (p = 0.6849) between the supernatant treated
with bismuth and the untreated control at the dilutions
studied.
As for the effect of the compounds on the Stx 933
W-encoding phage, a statistically significant decrease
(p < 0.05) was observed in the titer of the phage treated
with both CBHG and CBCHP in comparison with the
untreated titer. The decrease in the titer of the phage
was 90% for a CBHG dilution of 1/3, which corresponds
to a bismuth concentration of 10 mg/ml; and 86% for aFigure 1 Microscopy of monolayers of Vero cells. A. Normal monolaye
C. With 50% cytotoxicity 1/16 CBHG 3 mg/ml. D. With 80% cytotoxicity 1/2CBHG dilution of 1/6, which is equivalent to a bismuth
concentration of 5 mg/ml. In the tests performed with
CBCHP, the decrease in the titer of the phage was 82% for
a CBCHP dilution of 1/3, which corresponds to a bismuth
concentration of 10 mg/ml; and 73% for a CBCHP dilu-
tion of 1/6, which is equivalent to a bismuth concentration
of 5 mg/ml (Table 3 and Figure 2).Discussion
As a result of the anti-diarrheal activity exhibited by bis-
muth compounds in the treatment of various pathologies
associated with infections of the digestive apparatus in
humans, the possible mechanisms of action of these
compounds have been studied with renewed interest. In
choosing CBHG as our object of study, we considered
the following advantages: a) the bismuth in CBHG is in
a colloidal state; b) the bismuth in CBHG does not ap-
pear in the form of salt, such as salicylate, subsalicylate
or subgallate; c) the medicinal specialty CBCHP is an
anti-diarrheal drug for oral use suitable for administra-
tion in both children and adults, which was developed
in Argentina and has been on the market for over 60 years
at a low cost.
We based our study on the analysis of the effect of
CBHG and of CBCHP in differing concentrations, all
within the usual approved dosage, on STEC strains and
their virulence factors.
First, we assessed the sensitivity of STEC to CBHG and
CBCHP. The MIC is the most commonly used indicator
in choosing an antimicrobial therapy. In all cases tested,
MIC values were within the order of bismuth concentra-
tions of 6 and 10 mg/ml. The standard concentration of
bismuth both in CBHG and in CBCHP is 30 mg/ml, three
to five times higher than the MICs found. Therefore,
STEC O157:H7 is sensitive to treatment with CBHG at
lower concentrations than those usually used in therapeu-
tics and at the concentrations reached in vivo in the gutr, 1/32 CBHG 3 mg/ml. B. With 20% cytotoxicity, 1/4 CBCHP 3 mg/ml.
CBHG 3 mg/ml.
Table 3 Effect of CBHG and CBCHP on the 933 W Shiga toxin-encoding phage
Bismuth concentration (mg/ml) Phage titer (PFU/ml) Percentage of reduction (%) Phage titer (PFU/ml) Percentage of reduction (%)
0 2.6 × 103 ± 6.1 × 102 3.9 × 103 ± 2.1 × 102
CBCHP1 CBHG2
1.25 1.1 × 103 ± 4.9 × 102* 48 9.3 × 102 ± 2.5 × 102** 76
2.5 1.0 × 103 ± 3.9 × 102* 56 7.4 × 102 ± 1.3 × 102** 80
5 7.2 × 102 ± 1.1 × 102* 73 4.8 × 102 ± 5.0 × 101** 86
10 4.2 × 102 ± 2.0 × 102* 82 3.8 × 102 ± 6.0 × 101** 90
*P < 0.05, **P < 0.001, results expressed as the mean ± the SD of five experiments.
1CBCHP: Chobet® Bismuth Cream with Pectin, 2CBHG: colloidal bismuth hydroxide gel.
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obtained show higher sensitivity to CBCHP.
Bacterial resistance is a natural biological phenomenon
whose most serious consequence is the failure of anti-
microbial therapy, with the resulting increase in morbi-
mortality and in the cost of treatment. To date, it has
not been possible to find any publication providing data
on bacterial resistance to bismuth.
Both CBHG and the CBCHP have demonstrated their
ability to attach to and drag the STEC studied. CBHG
exhibited a greater ability to attach to bacterial cells and
drag them with slight centrifugation. The virulence of the
bacterial strains is directly related to their ability to attach
to the gastrointestinal epithelial walls [34]. The mechanical
attachment to the used compounds would obstruct the
bacterial attachment to the gastrointestinal epithelium,
preventing colonization and favoring the rapid expulsion
of pathogens outside the tract.
Furthermore, the data obtained show a significant re-
duction in the cytotoxic activity of Stx on Vero cells with
subinhibitory and subclinical concentrations of both CBHG
and CBCHP. No significant differences (p < 0.05) were
observed compared to controls with regard to the quanti-
fication of toxins by immunoadsorption. Therefore, we
suggest that the decrease in the activity of Stx is the result
of the direct interaction of CBHG with the activity of
toxins on eukaryotic cells.
The activity of Stx is directly related to the enzymatic
function of the cytotoxic subunit A [35]. Also, the asso-
ciation of the toxin with severe systemic pathologiesFigure 2 Photographs of incubated phage lysis plates. A. Without bism
D. With 10 mg/ml of bismuth.implies differences in the pentameric subunit B and in
its binding affinity to the Gb3 receptor in eukaryotic cells
[36]. Although some compounds can act as neutralizers
in the binding process of the toxin to its receptor, thus
generating inhibition of cytotoxicity on Vero cells [37],
we consider that the effect observed may be related to
the fixation of bismuth on one or more cysteine-rich
Stx sites involved in cytotoxicity [38,39].
The results obtained in tests with CBHG and CBCHP
on the free bacteriophage are very promising, with reduc-
tions of 80 and 90% in the phage titer. Stx damages endo-
thelial and renal tubular cells, and is therefore considered
a major virulence factor [40]. Stx1 and Stx2 are encoded
in the lambdoid prophage genome, and release phage
particles which infect other neighboring cells or which
remain in the medium as potential vehicles of virulence
genes [35]. The deactivation of the free bacteriophage,
caused by CBHG and by CBCHP, would inhibit the spread
of Stx-encoding genes to other uninfected cells, which in
turn would prevent the generation of new Stx-producing
strains.
Conclusions
We believe that the results obtained in this study are very
promising from a therapeutic point of view in the progno-
sis of HUS, and that the possibility of using CBHG as a
preventive measure should be assessed in the event of
diagnosis or suspicion of infection by E. coli O157:H7 or
other Shiga toxigenic strains such as the recently emerging
serotype O104:H4.uth. B. With 1.25 mg/ml of bismuth. C. With 5 mg/ml of bismuth.
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